📊 BIOA Key Takeaways
Is BioAge Labs, Inc. (BIOA) a Good Investment?
BioAge Labs is a development-stage biopharmaceutical company with a fortress balance sheet ($189M cash, zero debt) providing approximately 2.3 years of operational runway. However, the company is pre-commercial with only $9M in revenue and burning $82M annually in free cash flow, making financial viability entirely dependent on successful drug development and commercialization execution.
BioAge Labs has a strong balance sheet with substantial cash, no long-term debt, and very high liquidity, which provides meaningful funding capacity for a clinical-stage biotech business. However, fundamentals remain weak from an earnings and cash generation standpoint, with very large operating losses, deeply negative margins, and materially negative free cash flow relative to limited revenue. The company appears financially stable in the near term, but improvement in revenue quality, pipeline execution, and cash burn efficiency is necessary to strengthen the fundamental outlook.
Why Buy BioAge Labs, Inc. Stock? BIOA Key Strengths
- Strong balance sheet with $189M in cash and zero long-term debt
- Exceptional liquidity position (14.24x current ratio) mitigates near-term solvency risk
- Absence of debt burden provides maximum operational and strategic flexibility
- Large cash balance of $215.57M supports operations and reduces near-term financing pressure
- Debt-free capital structure and strong current ratio of 11.87x indicate solid financial health
- Low liability base relative to equity provides balance sheet flexibility
BIOA Stock Risks: BioAge Labs, Inc. Investment Risks
- Massive annual free cash flow burn of $82.3M against minimal revenue of $9M
- Pre-commercial stage with unproven product-market fit and limited commercialization traction
- Typical pharma development risk: clinical programs may fail, regulatory approvals uncertain, and products may never reach viable market
- Operating margin of -1087.7% and net margin of -923.8% show an unsustainable profitability profile
- Operating cash flow of -$53.38M and free cash flow of -$53.98M indicate continued cash burn
- Revenue base remains very small at $5.92M, limiting visibility into durable commercial-scale growth
Key Metrics to Watch
- Cash burn rate trajectory and remaining cash runway duration
- Revenue growth rate and product pipeline advancement toward commercialization
- Clinical trial data releases and regulatory approval progress
- Quarterly operating cash burn relative to cash balance
- Revenue growth quality and progression toward lower operating losses
BioAge Labs, Inc. (BIOA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.24x current ratio provides a solid financial cushion.
BIOA Profit Margin, ROE & Profitability Analysis
BIOA vs Healthcare Sector: How BioAge Labs, Inc. Compares
How BioAge Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioAge Labs, Inc. Stock Overvalued? BIOA Valuation Analysis 2026
Based on fundamental analysis, BioAge Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioAge Labs, Inc. Balance Sheet: BIOA Debt, Cash & Liquidity
BIOA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioAge Labs, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.63 indicates the company is currently unprofitable.
BIOA Revenue Growth, EPS Growth & YoY Performance
BIOA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$12.9M | $-0.56 |
| Q2 2025 | N/A | -$12.9M | $-0.60 |
| Q1 2025 | $1.5M | -$12.9M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioAge Labs, Inc. Dividends, Buybacks & Capital Allocation
BIOA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioAge Labs, Inc. (CIK: 0001709941)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIOA
What is the AI rating for BIOA?
BioAge Labs, Inc. (BIOA) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIOA's key strengths?
Claude: Strong balance sheet with $189M in cash and zero long-term debt. Exceptional liquidity position (14.24x current ratio) mitigates near-term solvency risk. ChatGPT: Large cash balance of $215.57M supports operations and reduces near-term financing pressure. Debt-free capital structure and strong current ratio of 11.87x indicate solid financial health.
What are the risks of investing in BIOA?
Claude: Massive annual free cash flow burn of $82.3M against minimal revenue of $9M. Pre-commercial stage with unproven product-market fit and limited commercialization traction. ChatGPT: Operating margin of -1087.7% and net margin of -923.8% show an unsustainable profitability profile. Operating cash flow of -$53.38M and free cash flow of -$53.98M indicate continued cash burn.
What is BIOA's revenue and growth?
BioAge Labs, Inc. reported revenue of $9.0M.
Does BIOA pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
Where can I find BIOA SEC filings?
Official SEC filings for BioAge Labs, Inc. (CIK: 0001709941) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIOA's EPS?
BioAge Labs, Inc. has a diluted EPS of $-2.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIOA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, BioAge Labs, Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIOA stock overvalued or undervalued?
Valuation metrics for BIOA: ROE of -29.6% (sector avg: 15%), net margin of -896.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BIOA stock in 2026?
Our dual AI analysis gives BioAge Labs, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIOA's free cash flow?
BioAge Labs, Inc.'s operating cash flow is $-81.6M, with capital expenditures of $719.0K. FCF margin is -915.5%.
How does BIOA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -896.1% (avg: 12%), ROE -29.6% (avg: 15%), current ratio 14.24 (avg: 2).